AKT1 and cancer: Thus, it will be interesting to explore whether the increase in E6/E7 expression, which is observed under treatment with PI3K/AKT/mTORC2 inhibitors may render hypoxic HPV-positive cancer cells more vulnerable towards E6/E7-targeting immunotherapy.